Agios to Present at BofA Securities 2024 Health Care Conference on May 16

Agios Pharmaceuticals, Inc., a leading company in cellular metabolism and PK activation, has announced its participation in the BofA Securities 2024 Health Care Conference. The company is scheduled to present on Thursday, May 16, 2024, at 11:40 a.m. ET. The presentation will be available through a live webcast accessible via the "Events & Presentations" section of the Investors page on the company's website. Additionally, the webcast will be archived and available for replay for at least two weeks following the event.

Agios Pharmaceuticals is recognized for its pioneering work in PK activation and is committed to developing transformative therapies for patients suffering from rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency in the United States. This therapy represents the first disease-modifying treatment for this chronic and debilitating form of hemolytic anemia.

Agios is leveraging its extensive scientific expertise in classical hematology and its leadership in cellular metabolism and rare hematologic diseases to advance a robust pipeline of investigational medicines. Their development programs include treatments for alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia, and phenylketonuria (PKU). Furthermore, Agios is also working on a preclinical TMPRSS6 siRNA, which is being explored as a potential treatment for polycythemia vera.